Compare AbbVie Inc (ABBV) vs Global X CleanTech (CTEC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Global X CleanTech — how do they compare? AbbVie Inc trades at $253.71 (market cap $449.91B), while Global X CleanTech trades at $58. The key difference: AbbVie Inc pays a 2.72% dividend while Global X CleanTech pays none, and AbbVie Inc is trading nearer its 52-week high, Global X CleanTech nearer its low. Which is the better fit depends on your goals.
| ABBV | CTEC | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $78.11 |
52-Week Low | $184.85 | $38.45 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
CTEC trades at $62.95, up 2.15% today, but technical indicators show a bearish trend with moving averages signaling caution. The stock faces resistance near $63 with support at $61. Recent news highlights Deutsche Bank maintaining a buy rating ahead of the company's Capital Markets Day, viewing it as a credibility test for growth targets. Financial ratios remain undisclosed in current data.
The outlook hinges on execution of growth targets, with potential upside if management delivers on guidance. Risks include competitive pressures and market volatility. Analyst optimism exists, but investors need confirmation of fundamental improvements during upcoming corporate events to drive sustained price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →
